Catalent Raises Guidance for Fiscal 2020
February 03 2020 - 9:46AM
Dow Jones News
By Amber Burton
Catalent Inc. (CTLT) raised guidance for fiscal 2020 to account
for the acquisition of Bristol-Myers Squibb Co.'s (BMY)
manufacturing and packaging facility in Italy.
The pharmaceutical, biotech and consumer health company on
Monday said it now expects adjusted earnings of between $307
million and $331 million, compared with earlier guidance of $300
million-$330 million.
It also forecasted revenue of between $2.87 billion to $2.95
billion, compared with previous guidance of $2.78 billion-$2.88
billion.
Analysts polled by FactSet expect revenue of $2.85 billion for
the fiscal year.
On Monday, the company reported adjusted earnings of 45 cents on
revenue of $721.4 million in the second quarter.
Write to Amber Burton at amber.burton@wsj.com
(END) Dow Jones Newswires
February 03, 2020 09:31 ET (14:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
